Vijay Pande
Showing 16–19 of 19 transcripts.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z27 min
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe
This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z22 min
a16z Podcast | When (and How) Biology Becomes Engineering
The event details the transformative shift in biology from a stochastic, discovery-based science to a standardized engineering discipline that treats biological components as predictable, interchangeable parts. Interdisciplinary innovation and machine learning now drive this transition by enabling repeatable design-build-refine cycles that replace traditional high-risk experimentation with data-driven predictability. This engineering mindset aims to commercialize biological platforms through measurable success rates and sustainable infrastructure, ultimately making previously impossible medical and industrial goals achievable through compounding technological improvements.